| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $658,844,374 ) (Continued on the next page) |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | U01NS153995 | An Intermediate-Size Expanded Access Protocol (EAP) for NUZ-001 in People with Amyotrophic Lateral Sclerosis (NUZ-001 EAP) | 000 | 1 | NIH | 8/28/2026 | $8,276,544 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K99AR084551 | Non-canonical transcriptional activation of MITF in pigment cells. | 000 | 1 | NIH | 4/8/2026 | $107,784 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K99MH141141 | Investigating the genetic modulation of phenotypic and transcriptomic convergence in bipolar disorder and schizophrenia | 000 | 1 | NIH | 8/31/2026 | $130,140 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21HD123465 | Small molecule PTH1R inverse agonists as a therapy for Jansen's Metaphyseal Chondrodysplasia | 000 | 1 | NIH | 9/17/2026 | $435,794 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01HL182978 | Clinical and Physiological Determinants of Pregnancy-Related Cardiovascular Complications | 000 | 1 | NIH | 9/10/2026 | $893,837 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21HD120605 | Repurposing drugs for fertility preservation | 000 | 1 | NIH | 9/17/2026 | $448,789 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21HD120605 | Repurposing drugs for fertility preservation | 001 | 1 | NIH | 9/18/2026 | $0 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01DK144165 | Proximal Splenic Artery Embolization for Treatment of Refractory Ascites in Decompensated Cirrhosis | 000 | 1 | NIH | 9/16/2026 | $660,048 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA303617 | Assessing the Effectiveness and Implementation of group based Tobacco Treatment for older individuals undergoing lung cancer screening | 000 | 1 | NIH | 9/17/2026 | $713,493 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01DA065550 | Longitudinal Trajectories of OUD Care following Initial Engagement with a Low-Threshold Bridge Clinic | 000 | 1 | NIH | 9/17/2026 | $776,528 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21AG104008 | Pilot RCT of MBCT vs Health Enhancement Program for the Chronic Pain-Early Cognitive Decline Co-Morbidity Among Older Black Adults | 000 | 1 | NIH | 9/8/2026 | $247,500 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R03AG100782 | Improve and Validate Amyloid Pathology Visualization and Analysis in Intact Brain Samples | 000 | 1 | NIH | 9/17/2026 | $329,220 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K00MH147882 | Social Isolation and Metabolic Homeostasis: Investigating the Role of Oxytocin in Modulating Hypothalamic Glucose Sensing | 001 | 2 | NIH | 9/9/2026 | $87,631 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA307174 | Impact of IDH mutation on the glioma-neuronal microenvironment | 000 | 1 | NIH | 9/16/2026 | $632,453 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K00MH147882 | Social Isolation and Metabolic Homeostasis: Investigating the Role of Oxytocin in Modulating Hypothalamic Glucose Sensing | 001 | 2 | NIH | 9/9/2026 | -$87,631 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA316243 | Targeting CDK2 in CDK4/6 inhibitor-resistant HR-positive/HER2-negative breast cancer | 000 | 1 | NIH | 9/9/2026 | $660,843 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R37CA309465 | Advanced Neurovascular Imaging Using 7T MRI to Assess Long-Term Effects of Proton Radiotherapy in Pediatric Brain Tumor Survivors | 000 | 1 | NIH | 9/17/2026 | $702,330 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K00MH147882 | Social Isolation and Metabolic Homeostasis: Investigating the Role of Oxytocin in Modulating Hypothalamic Glucose Sensing | 000 | 2 | NIH | 9/7/2026 | $87,631 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R34AT013833 | Virtual Rheum: The Development of a Virtual Mind-Body Resiliency Intervention for Patients with ANCA-Associated Vasculitis and Systemic Lupus Erythematosus | 000 | 1 | NIH | 9/16/2026 | $770,399 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K00CA294164 | Multimodal Imaging Biomarkers for Early Detection of Glioblastoma Progression | 000 | 3 | NIH | 9/10/2026 | $103,428 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01HL189470 | Reducing Arterial Inflammation using Eplerenone and Statins to Augment Cardiovascular Health in HIV | 000 | 1 | NIH | 9/10/2026 | $773,096 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | AY2AX000238 | An Adaptive Clinical Trial Platform for Early Detection and Prevention of Alzheimer's Disease Pathology | 000 | 1 | NIH | 9/16/2026 | $7,170,476 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K08HL179467 | Deep learning to assess the role of early renal fibrosis on cardiac remodeling | 000 | 1 | NIH | 9/4/2026 | $170,640 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K99MH142686 | Leveraging Ambulatory Technology to Assess Cognitive-Affective Processes in Suicidal Ideation Among High-Risk Adolescents | 000 | 1 | NIH | 9/17/2026 | $128,924 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01MD021855 | Cutting Out Stigma: A Barbershop-Based Cluster-Randomized Trial to Improve HIV Testing, PrEP Uptake, and Stigma Reduction | 000 | 1 | NIH | 9/17/2026 | $832,865 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R37CA299872 | Elucidating mechanisms of resistance to mutant-selective P13Ka inhibitors | 000 | 1 | NIH | 9/4/2026 | $634,378 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01MH143822 | Harnessing routine clinical suicide risk assessment for machine learning-guidedprediction and precision treatment in outpatient behavioral health care | 000 | 1 | NIH | 9/3/2026 | $824,404 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01FD008525 | Phase 2 Study of EPN-701 for Treatment of Calciphylaxis (IND: 129344; September 14, 2022) | 000 | 1 | FDA | 9/29/2026 | $1,418,815 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01FD008525 | Phase 2 Study of EPN-701 for Treatment of Calciphylaxis (IND: 129344; September 14, 2022) | 000 | 1 | FDA | 9/29/2026 | $556,835 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01FD008525 | Phase 2 Study of EPN-701 for Treatment of Calciphylaxis (IND: 129344; September 14, 2022) | 000 | 1 | FDA | 9/29/2026 | $163,847 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01FD008525 | Phase 2 Study of EPN-701 for Treatment of Calciphylaxis (IND: 129344; September 14, 2022) | 000 | 1 | FDA | 9/29/2026 | $277,020 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01FD008525 | Phase 2 Study of EPN-701 for Treatment of Calciphylaxis (IND: 129344; September 14, 2022) | 000 | 1 | FDA | 9/29/2026 | $45,898 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | P01CA295486 | High Resolution Dissection of Response Mechanisms to Chemoradiation in Gastrointestinal Cancers | 000 | 1 | NIH | 9/4/2026 | $1,652,508 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | NU50CK000676 | Virtual and Integrated Simulation and Implementation for Building Learning and Emergency preparedness (VISIBLE) strengthens readiness for emerging infectious disease prevention, detection, & response. | 00 | 1 | CDC | 9/25/2026 | $500,000 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K99CA307323 | Investigation into the regulation of mitochondrial dynamics, intra-organelle communication, and metabolic reprogramming by the PKA-fusion oncoprotein | 000 | 1 | NIH | 9/3/2026 | $161,676 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R61AR086955 | Toward Biomarker-Guided Fibromyalgia Treatment with Non-Invasive Vagus Nerve Stimulation | 000 | 1 | NIH | 9/4/2026 | $227,800 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01HD116609 | Mechanistic intersection between placental vascular and newborn neuronal development | 003 | 1 | NIH | 2/26/2026 | $36,131 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21DA065889 | Precision Risk Modeling to Reduce Opioid Overdose Deaths among Individuals Experiencing Homelessness | 000 | 1 | NIH | 5/20/2026 | $476,808 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21DA065889 | Precision Risk Modeling to Reduce Opioid Overdose Deaths among Individuals Experiencing Homelessness | 001 | 1 | NIH | 6/25/2026 | $0 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21AI199818 | Harnessing lysosome trafficking for enhanced antigen presentation | 000 | 1 | NIH | 5/22/2026 | $228,462 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA315856 | Spatial control of synthetic immunogenic cytotoxicity for the treatment of locally advanced lung cancer | 000 | 1 | NIH | 6/8/2026 | $682,140 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K08AR086316 | Unraveling shared and unique mechanisms of autoimmunity using systems immunology approaches: Regulatory T cell dysfunction in Lupus | 000 | 1 | NIH | 5/20/2026 | $165,240 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21AR088883 | Role of Gq signaling for PTH1R-dependent bone growth | 000 | 1 | NIH | 9/23/2026 | $200,256 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01DK146327 | BMP2/6 ligand formation and function in development and iron homeostasis | 000 | 1 | NIH | 1/26/2026 | $813,961 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS149686 | Circadian regulation of reperfusion efficacy in acute ischemic stroke | 000 | 1 | NIH | 6/12/2026 | $648,672 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01DK146206 | c-Kit receptor signaling in the modulation of collecting duct function | 001 | 1 | NIH | 5/14/2026 | $29,896 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01HL179112 | Deciphering respiratory disease mechanisms through integration of genomic and functional data across massive global biobanks | 000 | 2 | NIH | 6/12/2026 | $773,633 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01MH138281 | Electronic Partner Notification for STIs: A Syndemic Approach to Improve HIV and STI Service Access in MA | 000 | 1 | NIH | 3/19/2026 | $855,983 |
| | 2026 | 2026 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01DK146206 | c-Kit receptor signaling in the modulation of collecting duct function | 000 | 1 | NIH | 3/19/2026 | $110,865 |
|
